Orchestra BioMed Holdings Inc. Cash Flow Conversion Efficiency
Orchestra BioMed Holdings Inc. cash flow conversion efficiency. Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has a cash flow conversion efficiency ratio of -0.657x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.33 Million) by net assets ($29.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Orchestra BioMed Holdings Inc. (2020–2025)
Cash flow conversion efficiency of Orchestra BioMed Holdings Inc. from 2020 to 2025. This chart illustrates how Orchestra BioMed Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Orchestra BioMed Holdings Inc. share price for real-time trading data and today's change.
Orchestra BioMed Holdings Inc. Cash Flow Conversion Ratio Explained
Orchestra BioMed Holdings Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Orchestra BioMed Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their cash flow conversion efficiency. Also see Orchestra BioMed Holdings Inc. stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Paiho Ltd
TW:9938
|
0.049x |
|
Symtek Automation Asia Co Ltd
TW:6438
|
0.039x |
|
FLAT GLASS GROUP H YC-25
F:72T
|
N/A |
|
RCE Capital Berhad
KLSE:9296
|
0.045x |
|
John Marshall Bancorp Inc
NASDAQ:JMSB
|
0.018x |
|
Jiangsu Nanfang Medical
SHG:603880
|
0.077x |
|
Aurora Cannabis Inc
TO:ACB
|
-0.008x |
|
ADTRAN Inc
NASDAQ:ADTN
|
0.025x |
Annual Cash Flow Conversion Efficiency for Orchestra BioMed Holdings Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Orchestra BioMed Holdings Inc. from 2020 to 2025. Review Orchestra BioMed Holdings Inc. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $63.38 Million | $-48.96 Million | -0.773x | +49.64% |
| 2024-12-31 | $32.96 Million | $-50.56 Million | -1.534x | -126.29% |
| 2023-12-31 | $68.04 Million | $-46.13 Million | -0.678x | -21.59% |
| 2022-12-31 | $52.53 Million | $-29.29 Million | -0.558x | -304.40% |
| 2021-12-31 | $-71.23 Million | $-19.43 Million | 0.273x | -49.43% |
| 2020-12-31 | $-48.54 Million | $-26.18 Million | 0.539x | -- |
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more